nodes	percent_of_prediction	percent_of_DWPC	metapath
Trabectedin—CYP2E1—liver cancer	0.534	1	CbGaD
Trabectedin—CYP2C19—Sorafenib—liver cancer	0.0352	0.261	CbGbCtD
Trabectedin—CYP2C9—Sorafenib—liver cancer	0.0293	0.217	CbGbCtD
Trabectedin—CYP2D6—Sorafenib—liver cancer	0.0268	0.198	CbGbCtD
Trabectedin—Hepatic pain—Sorafenib—liver cancer	0.0225	0.143	CcSEcCtD
Trabectedin—CYP3A4—Sorafenib—liver cancer	0.017	0.126	CbGbCtD
Trabectedin—CYP2D6—Doxorubicin—liver cancer	0.0162	0.12	CbGbCtD
Trabectedin—CYP3A4—Doxorubicin—liver cancer	0.0103	0.0766	CbGbCtD
Trabectedin—Peripheral sensory neuropathy—Sorafenib—liver cancer	0.00657	0.0418	CcSEcCtD
Trabectedin—Neutropenic sepsis—Epirubicin—liver cancer	0.004	0.0255	CcSEcCtD
Trabectedin—Neutropenic sepsis—Doxorubicin—liver cancer	0.0037	0.0236	CcSEcCtD
Trabectedin—Mucosal inflammation—Sorafenib—liver cancer	0.00339	0.0216	CcSEcCtD
Trabectedin—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.00243	0.0155	CcSEcCtD
Trabectedin—Septic shock—Epirubicin—liver cancer	0.0023	0.0146	CcSEcCtD
Trabectedin—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.00225	0.0143	CcSEcCtD
Trabectedin—Multi-organ failure—Epirubicin—liver cancer	0.00213	0.0136	CcSEcCtD
Trabectedin—Septic shock—Doxorubicin—liver cancer	0.00213	0.0135	CcSEcCtD
Trabectedin—Rhabdomyolysis—Sorafenib—liver cancer	0.00212	0.0135	CcSEcCtD
Trabectedin—Multi-organ failure—Doxorubicin—liver cancer	0.00197	0.0125	CcSEcCtD
Trabectedin—Hepatic failure—Sorafenib—liver cancer	0.00152	0.00965	CcSEcCtD
Trabectedin—Dehydration—Sorafenib—liver cancer	0.00127	0.00807	CcSEcCtD
Trabectedin—Mucosal inflammation—Epirubicin—liver cancer	0.00125	0.00798	CcSEcCtD
Trabectedin—Abdominal pain upper—Sorafenib—liver cancer	0.00125	0.00792	CcSEcCtD
Trabectedin—Hypokalaemia—Sorafenib—liver cancer	0.00124	0.00789	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00123	0.00781	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Sorafenib—liver cancer	0.0012	0.00765	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Epirubicin—liver cancer	0.00117	0.00743	CcSEcCtD
Trabectedin—Mucosal inflammation—Doxorubicin—liver cancer	0.00116	0.00738	CcSEcCtD
Trabectedin—Febrile neutropenia—Epirubicin—liver cancer	0.00115	0.00734	CcSEcCtD
Trabectedin—Neutropenia—Sorafenib—liver cancer	0.0011	0.00701	CcSEcCtD
Trabectedin—Skin hyperpigmentation—Doxorubicin—liver cancer	0.00108	0.00687	CcSEcCtD
Trabectedin—Febrile neutropenia—Doxorubicin—liver cancer	0.00107	0.00679	CcSEcCtD
Trabectedin—Weight decreased—Sorafenib—liver cancer	0.00107	0.00678	CcSEcCtD
Trabectedin—Infestation NOS—Sorafenib—liver cancer	0.00105	0.00669	CcSEcCtD
Trabectedin—Infestation—Sorafenib—liver cancer	0.00105	0.00669	CcSEcCtD
Trabectedin—Stomatitis—Sorafenib—liver cancer	0.00102	0.00652	CcSEcCtD
Trabectedin—Jaundice—Sorafenib—liver cancer	0.00102	0.00652	CcSEcCtD
Trabectedin—Hepatobiliary disease—Sorafenib—liver cancer	0.000994	0.00632	CcSEcCtD
Trabectedin—Hepatomegaly—Epirubicin—liver cancer	0.000981	0.00624	CcSEcCtD
Trabectedin—Haemoglobin—Sorafenib—liver cancer	0.000948	0.00603	CcSEcCtD
Trabectedin—Haemorrhage—Sorafenib—liver cancer	0.000943	0.006	CcSEcCtD
Trabectedin—Connective tissue disorder—Sorafenib—liver cancer	0.000927	0.0059	CcSEcCtD
Trabectedin—Hepatomegaly—Doxorubicin—liver cancer	0.000907	0.00577	CcSEcCtD
Trabectedin—Necrosis—Epirubicin—liver cancer	0.000884	0.00563	CcSEcCtD
Trabectedin—Flushing—Sorafenib—liver cancer	0.000875	0.00557	CcSEcCtD
Trabectedin—Angiopathy—Sorafenib—liver cancer	0.000856	0.00544	CcSEcCtD
Trabectedin—Mediastinal disorder—Sorafenib—liver cancer	0.00085	0.00541	CcSEcCtD
Trabectedin—Alopecia—Sorafenib—liver cancer	0.000833	0.0053	CcSEcCtD
Trabectedin—Mental disorder—Sorafenib—liver cancer	0.000826	0.00526	CcSEcCtD
Trabectedin—Liver injury—Epirubicin—liver cancer	0.000825	0.00525	CcSEcCtD
Trabectedin—Malnutrition—Sorafenib—liver cancer	0.000821	0.00522	CcSEcCtD
Trabectedin—Necrosis—Doxorubicin—liver cancer	0.000818	0.00521	CcSEcCtD
Trabectedin—Dysgeusia—Sorafenib—liver cancer	0.000804	0.00512	CcSEcCtD
Trabectedin—Extravasation—Epirubicin—liver cancer	0.000796	0.00506	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Epirubicin—liver cancer	0.000763	0.00486	CcSEcCtD
Trabectedin—Liver injury—Doxorubicin—liver cancer	0.000763	0.00486	CcSEcCtD
Trabectedin—Anaemia—Sorafenib—liver cancer	0.000759	0.00483	CcSEcCtD
Trabectedin—Syncope—Sorafenib—liver cancer	0.000736	0.00468	CcSEcCtD
Trabectedin—Extravasation—Doxorubicin—liver cancer	0.000736	0.00468	CcSEcCtD
Trabectedin—Leukopenia—Sorafenib—liver cancer	0.000735	0.00468	CcSEcCtD
Trabectedin—Loss of consciousness—Sorafenib—liver cancer	0.000722	0.00459	CcSEcCtD
Trabectedin—Cough—Sorafenib—liver cancer	0.000716	0.00456	CcSEcCtD
Trabectedin—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000706	0.00449	CcSEcCtD
Trabectedin—Musculoskeletal pain—Epirubicin—liver cancer	0.000703	0.00447	CcSEcCtD
Trabectedin—Arthralgia—Sorafenib—liver cancer	0.000699	0.00445	CcSEcCtD
Trabectedin—Myalgia—Sorafenib—liver cancer	0.000699	0.00445	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000694	0.00442	CcSEcCtD
Trabectedin—Pulmonary embolism—Epirubicin—liver cancer	0.000694	0.00442	CcSEcCtD
Trabectedin—Injection site reaction—Epirubicin—liver cancer	0.00069	0.00439	CcSEcCtD
Trabectedin—Infection—Sorafenib—liver cancer	0.000666	0.00424	CcSEcCtD
Trabectedin—Shock—Sorafenib—liver cancer	0.000659	0.00419	CcSEcCtD
Trabectedin—Nervous system disorder—Sorafenib—liver cancer	0.000657	0.00418	CcSEcCtD
Trabectedin—Thrombocytopenia—Sorafenib—liver cancer	0.000656	0.00417	CcSEcCtD
Trabectedin—Skin disorder—Sorafenib—liver cancer	0.000651	0.00414	CcSEcCtD
Trabectedin—Musculoskeletal pain—Doxorubicin—liver cancer	0.00065	0.00414	CcSEcCtD
Trabectedin—Pulmonary embolism—Doxorubicin—liver cancer	0.000642	0.00409	CcSEcCtD
Trabectedin—Anorexia—Sorafenib—liver cancer	0.000639	0.00406	CcSEcCtD
Trabectedin—Injection site reaction—Doxorubicin—liver cancer	0.000638	0.00406	CcSEcCtD
Trabectedin—Pulmonary oedema—Epirubicin—liver cancer	0.000618	0.00393	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00061	0.00388	CcSEcCtD
Trabectedin—Sepsis—Epirubicin—liver cancer	0.000602	0.00383	CcSEcCtD
Trabectedin—Dyspnoea—Sorafenib—liver cancer	0.000597	0.0038	CcSEcCtD
Trabectedin—Dyspepsia—Sorafenib—liver cancer	0.00059	0.00375	CcSEcCtD
Trabectedin—Decreased appetite—Sorafenib—liver cancer	0.000582	0.00371	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000579	0.00369	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Sorafenib—liver cancer	0.000579	0.00368	CcSEcCtD
Trabectedin—Fatigue—Sorafenib—liver cancer	0.000578	0.00368	CcSEcCtD
Trabectedin—Constipation—Sorafenib—liver cancer	0.000573	0.00365	CcSEcCtD
Trabectedin—Pulmonary oedema—Doxorubicin—liver cancer	0.000572	0.00364	CcSEcCtD
Trabectedin—Hepatic failure—Epirubicin—liver cancer	0.000561	0.00357	CcSEcCtD
Trabectedin—Sepsis—Doxorubicin—liver cancer	0.000557	0.00355	CcSEcCtD
Trabectedin—Gastrointestinal pain—Sorafenib—liver cancer	0.000548	0.00349	CcSEcCtD
Trabectedin—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000536	0.00341	CcSEcCtD
Trabectedin—Abdominal pain—Sorafenib—liver cancer	0.00053	0.00337	CcSEcCtD
Trabectedin—Body temperature increased—Sorafenib—liver cancer	0.00053	0.00337	CcSEcCtD
Trabectedin—Hepatic failure—Doxorubicin—liver cancer	0.000519	0.0033	CcSEcCtD
Trabectedin—Hypersensitivity—Sorafenib—liver cancer	0.000494	0.00314	CcSEcCtD
Trabectedin—Asthenia—Sorafenib—liver cancer	0.000481	0.00306	CcSEcCtD
Trabectedin—Blood creatinine increased—Epirubicin—liver cancer	0.000472	0.003	CcSEcCtD
Trabectedin—Dehydration—Epirubicin—liver cancer	0.000469	0.00298	CcSEcCtD
Trabectedin—Abdominal pain upper—Epirubicin—liver cancer	0.00046	0.00293	CcSEcCtD
Trabectedin—Hypokalaemia—Epirubicin—liver cancer	0.000459	0.00292	CcSEcCtD
Trabectedin—Diarrhoea—Sorafenib—liver cancer	0.000458	0.00292	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000454	0.00289	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000444	0.00283	CcSEcCtD
Trabectedin—Dizziness—Sorafenib—liver cancer	0.000443	0.00282	CcSEcCtD
Trabectedin—Blood creatinine increased—Doxorubicin—liver cancer	0.000437	0.00278	CcSEcCtD
Trabectedin—Dehydration—Doxorubicin—liver cancer	0.000434	0.00276	CcSEcCtD
Trabectedin—Vomiting—Sorafenib—liver cancer	0.000426	0.00271	CcSEcCtD
Trabectedin—Abdominal pain upper—Doxorubicin—liver cancer	0.000426	0.00271	CcSEcCtD
Trabectedin—Hypokalaemia—Doxorubicin—liver cancer	0.000424	0.0027	CcSEcCtD
Trabectedin—Rash—Sorafenib—liver cancer	0.000422	0.00269	CcSEcCtD
Trabectedin—Dermatitis—Sorafenib—liver cancer	0.000422	0.00269	CcSEcCtD
Trabectedin—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00042	0.00267	CcSEcCtD
Trabectedin—Headache—Sorafenib—liver cancer	0.00042	0.00267	CcSEcCtD
Trabectedin—Pancytopenia—Epirubicin—liver cancer	0.000414	0.00263	CcSEcCtD
Trabectedin—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000411	0.00262	CcSEcCtD
Trabectedin—Neutropenia—Epirubicin—liver cancer	0.000407	0.00259	CcSEcCtD
Trabectedin—Nausea—Sorafenib—liver cancer	0.000398	0.00253	CcSEcCtD
Trabectedin—Weight decreased—Epirubicin—liver cancer	0.000394	0.00251	CcSEcCtD
Trabectedin—Infestation NOS—Epirubicin—liver cancer	0.000388	0.00247	CcSEcCtD
Trabectedin—Infestation—Epirubicin—liver cancer	0.000388	0.00247	CcSEcCtD
Trabectedin—Pancytopenia—Doxorubicin—liver cancer	0.000383	0.00243	CcSEcCtD
Trabectedin—Stomatitis—Epirubicin—liver cancer	0.000378	0.00241	CcSEcCtD
Trabectedin—Jaundice—Epirubicin—liver cancer	0.000378	0.00241	CcSEcCtD
Trabectedin—Neutropenia—Doxorubicin—liver cancer	0.000377	0.0024	CcSEcCtD
Trabectedin—Hepatobiliary disease—Epirubicin—liver cancer	0.000367	0.00234	CcSEcCtD
Trabectedin—Weight decreased—Doxorubicin—liver cancer	0.000365	0.00232	CcSEcCtD
Trabectedin—Agranulocytosis—Epirubicin—liver cancer	0.000362	0.00231	CcSEcCtD
Trabectedin—Infestation NOS—Doxorubicin—liver cancer	0.000359	0.00229	CcSEcCtD
Trabectedin—Infestation—Doxorubicin—liver cancer	0.000359	0.00229	CcSEcCtD
Trabectedin—Haemoglobin—Epirubicin—liver cancer	0.00035	0.00223	CcSEcCtD
Trabectedin—Stomatitis—Doxorubicin—liver cancer	0.00035	0.00223	CcSEcCtD
Trabectedin—Jaundice—Doxorubicin—liver cancer	0.00035	0.00223	CcSEcCtD
Trabectedin—Haemorrhage—Epirubicin—liver cancer	0.000349	0.00222	CcSEcCtD
Trabectedin—Oedema peripheral—Epirubicin—liver cancer	0.000343	0.00218	CcSEcCtD
Trabectedin—Connective tissue disorder—Epirubicin—liver cancer	0.000343	0.00218	CcSEcCtD
Trabectedin—Hepatobiliary disease—Doxorubicin—liver cancer	0.00034	0.00216	CcSEcCtD
Trabectedin—Agranulocytosis—Doxorubicin—liver cancer	0.000335	0.00213	CcSEcCtD
Trabectedin—Haemoglobin—Doxorubicin—liver cancer	0.000324	0.00206	CcSEcCtD
Trabectedin—Flushing—Epirubicin—liver cancer	0.000323	0.00206	CcSEcCtD
Trabectedin—Haemorrhage—Doxorubicin—liver cancer	0.000323	0.00205	CcSEcCtD
Trabectedin—Oedema peripheral—Doxorubicin—liver cancer	0.000318	0.00202	CcSEcCtD
Trabectedin—Connective tissue disorder—Doxorubicin—liver cancer	0.000317	0.00202	CcSEcCtD
Trabectedin—Angiopathy—Epirubicin—liver cancer	0.000316	0.00201	CcSEcCtD
Trabectedin—Mediastinal disorder—Epirubicin—liver cancer	0.000314	0.002	CcSEcCtD
Trabectedin—Alopecia—Epirubicin—liver cancer	0.000308	0.00196	CcSEcCtD
Trabectedin—Mental disorder—Epirubicin—liver cancer	0.000305	0.00194	CcSEcCtD
Trabectedin—Malnutrition—Epirubicin—liver cancer	0.000303	0.00193	CcSEcCtD
Trabectedin—Flushing—Doxorubicin—liver cancer	0.000299	0.0019	CcSEcCtD
Trabectedin—Dysgeusia—Epirubicin—liver cancer	0.000297	0.00189	CcSEcCtD
Trabectedin—Back pain—Epirubicin—liver cancer	0.000294	0.00187	CcSEcCtD
Trabectedin—Angiopathy—Doxorubicin—liver cancer	0.000293	0.00186	CcSEcCtD
Trabectedin—Mediastinal disorder—Doxorubicin—liver cancer	0.000291	0.00185	CcSEcCtD
Trabectedin—Alopecia—Doxorubicin—liver cancer	0.000285	0.00181	CcSEcCtD
Trabectedin—Mental disorder—Doxorubicin—liver cancer	0.000283	0.0018	CcSEcCtD
Trabectedin—Malnutrition—Doxorubicin—liver cancer	0.000281	0.00179	CcSEcCtD
Trabectedin—Anaemia—Epirubicin—liver cancer	0.00028	0.00178	CcSEcCtD
Trabectedin—Dysgeusia—Doxorubicin—liver cancer	0.000275	0.00175	CcSEcCtD
Trabectedin—Syncope—Epirubicin—liver cancer	0.000272	0.00173	CcSEcCtD
Trabectedin—Leukopenia—Epirubicin—liver cancer	0.000272	0.00173	CcSEcCtD
Trabectedin—Back pain—Doxorubicin—liver cancer	0.000272	0.00173	CcSEcCtD
Trabectedin—Loss of consciousness—Epirubicin—liver cancer	0.000267	0.0017	CcSEcCtD
Trabectedin—Cough—Epirubicin—liver cancer	0.000265	0.00168	CcSEcCtD
Trabectedin—Anaemia—Doxorubicin—liver cancer	0.000259	0.00165	CcSEcCtD
Trabectedin—Myalgia—Epirubicin—liver cancer	0.000258	0.00164	CcSEcCtD
Trabectedin—Arthralgia—Epirubicin—liver cancer	0.000258	0.00164	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000257	0.00163	CcSEcCtD
Trabectedin—Syncope—Doxorubicin—liver cancer	0.000252	0.0016	CcSEcCtD
Trabectedin—Leukopenia—Doxorubicin—liver cancer	0.000251	0.0016	CcSEcCtD
Trabectedin—Oedema—Epirubicin—liver cancer	0.000248	0.00158	CcSEcCtD
Trabectedin—Loss of consciousness—Doxorubicin—liver cancer	0.000247	0.00157	CcSEcCtD
Trabectedin—Infection—Epirubicin—liver cancer	0.000246	0.00157	CcSEcCtD
Trabectedin—Cough—Doxorubicin—liver cancer	0.000245	0.00156	CcSEcCtD
Trabectedin—Shock—Epirubicin—liver cancer	0.000244	0.00155	CcSEcCtD
Trabectedin—Nervous system disorder—Epirubicin—liver cancer	0.000243	0.00155	CcSEcCtD
Trabectedin—Thrombocytopenia—Epirubicin—liver cancer	0.000242	0.00154	CcSEcCtD
Trabectedin—Skin disorder—Epirubicin—liver cancer	0.000241	0.00153	CcSEcCtD
Trabectedin—Arthralgia—Doxorubicin—liver cancer	0.000239	0.00152	CcSEcCtD
Trabectedin—Myalgia—Doxorubicin—liver cancer	0.000239	0.00152	CcSEcCtD
Trabectedin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000237	0.00151	CcSEcCtD
Trabectedin—Anorexia—Epirubicin—liver cancer	0.000236	0.0015	CcSEcCtD
Trabectedin—Hypotension—Epirubicin—liver cancer	0.000231	0.00147	CcSEcCtD
Trabectedin—Oedema—Doxorubicin—liver cancer	0.000229	0.00146	CcSEcCtD
Trabectedin—Infection—Doxorubicin—liver cancer	0.000228	0.00145	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000226	0.00144	CcSEcCtD
Trabectedin—Shock—Doxorubicin—liver cancer	0.000225	0.00143	CcSEcCtD
Trabectedin—Nervous system disorder—Doxorubicin—liver cancer	0.000225	0.00143	CcSEcCtD
Trabectedin—Thrombocytopenia—Doxorubicin—liver cancer	0.000224	0.00143	CcSEcCtD
Trabectedin—Insomnia—Epirubicin—liver cancer	0.000224	0.00143	CcSEcCtD
Trabectedin—Skin disorder—Doxorubicin—liver cancer	0.000223	0.00142	CcSEcCtD
Trabectedin—Paraesthesia—Epirubicin—liver cancer	0.000222	0.00141	CcSEcCtD
Trabectedin—Dyspnoea—Epirubicin—liver cancer	0.000221	0.0014	CcSEcCtD
Trabectedin—Anorexia—Doxorubicin—liver cancer	0.000218	0.00139	CcSEcCtD
Trabectedin—Dyspepsia—Epirubicin—liver cancer	0.000218	0.00139	CcSEcCtD
Trabectedin—Decreased appetite—Epirubicin—liver cancer	0.000215	0.00137	CcSEcCtD
Trabectedin—Hypotension—Doxorubicin—liver cancer	0.000214	0.00136	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Epirubicin—liver cancer	0.000214	0.00136	CcSEcCtD
Trabectedin—Fatigue—Epirubicin—liver cancer	0.000214	0.00136	CcSEcCtD
Trabectedin—Constipation—Epirubicin—liver cancer	0.000212	0.00135	CcSEcCtD
Trabectedin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000209	0.00133	CcSEcCtD
Trabectedin—Insomnia—Doxorubicin—liver cancer	0.000207	0.00132	CcSEcCtD
Trabectedin—Paraesthesia—Doxorubicin—liver cancer	0.000206	0.00131	CcSEcCtD
Trabectedin—Dyspnoea—Doxorubicin—liver cancer	0.000204	0.0013	CcSEcCtD
Trabectedin—Gastrointestinal pain—Epirubicin—liver cancer	0.000203	0.00129	CcSEcCtD
Trabectedin—Dyspepsia—Doxorubicin—liver cancer	0.000202	0.00128	CcSEcCtD
Trabectedin—Decreased appetite—Doxorubicin—liver cancer	0.000199	0.00127	CcSEcCtD
Trabectedin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000198	0.00126	CcSEcCtD
Trabectedin—Fatigue—Doxorubicin—liver cancer	0.000198	0.00126	CcSEcCtD
Trabectedin—Constipation—Doxorubicin—liver cancer	0.000196	0.00125	CcSEcCtD
Trabectedin—Abdominal pain—Epirubicin—liver cancer	0.000196	0.00125	CcSEcCtD
Trabectedin—Body temperature increased—Epirubicin—liver cancer	0.000196	0.00125	CcSEcCtD
Trabectedin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000187	0.00119	CcSEcCtD
Trabectedin—Hypersensitivity—Epirubicin—liver cancer	0.000182	0.00116	CcSEcCtD
Trabectedin—Abdominal pain—Doxorubicin—liver cancer	0.000181	0.00115	CcSEcCtD
Trabectedin—Body temperature increased—Doxorubicin—liver cancer	0.000181	0.00115	CcSEcCtD
Trabectedin—Asthenia—Epirubicin—liver cancer	0.000178	0.00113	CcSEcCtD
Trabectedin—Diarrhoea—Epirubicin—liver cancer	0.000169	0.00108	CcSEcCtD
Trabectedin—Hypersensitivity—Doxorubicin—liver cancer	0.000169	0.00107	CcSEcCtD
Trabectedin—Asthenia—Doxorubicin—liver cancer	0.000164	0.00105	CcSEcCtD
Trabectedin—Dizziness—Epirubicin—liver cancer	0.000164	0.00104	CcSEcCtD
Trabectedin—Vomiting—Epirubicin—liver cancer	0.000157	0.001	CcSEcCtD
Trabectedin—Diarrhoea—Doxorubicin—liver cancer	0.000157	0.000998	CcSEcCtD
Trabectedin—Rash—Epirubicin—liver cancer	0.000156	0.000994	CcSEcCtD
Trabectedin—Dermatitis—Epirubicin—liver cancer	0.000156	0.000993	CcSEcCtD
Trabectedin—Headache—Epirubicin—liver cancer	0.000155	0.000987	CcSEcCtD
Trabectedin—Dizziness—Doxorubicin—liver cancer	0.000152	0.000964	CcSEcCtD
Trabectedin—Nausea—Epirubicin—liver cancer	0.000147	0.000936	CcSEcCtD
Trabectedin—Vomiting—Doxorubicin—liver cancer	0.000146	0.000927	CcSEcCtD
Trabectedin—Rash—Doxorubicin—liver cancer	0.000144	0.000919	CcSEcCtD
Trabectedin—Dermatitis—Doxorubicin—liver cancer	0.000144	0.000918	CcSEcCtD
Trabectedin—Headache—Doxorubicin—liver cancer	0.000144	0.000913	CcSEcCtD
Trabectedin—Nausea—Doxorubicin—liver cancer	0.000136	0.000866	CcSEcCtD
Trabectedin—CYP2D6—Metabolism—NAT2—liver cancer	1.82e-05	0.000105	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—JUN—liver cancer	1.82e-05	0.000105	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—HMOX1—liver cancer	1.82e-05	0.000105	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CRABP1—liver cancer	1.81e-05	0.000105	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—CTNNB1—liver cancer	1.81e-05	0.000104	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—NAT2—liver cancer	1.81e-05	0.000104	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—VEGFA—liver cancer	1.81e-05	0.000104	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—STAT3—liver cancer	1.79e-05	0.000103	CbGpPWpGaD
Trabectedin—SRC—Signaling by NGF—AKT1—liver cancer	1.78e-05	0.000103	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GOT2—liver cancer	1.78e-05	0.000103	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—VEGFA—liver cancer	1.77e-05	0.000102	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—CDKN1A—liver cancer	1.77e-05	0.000102	CbGpPWpGaD
Trabectedin—SRC—Immune System—BCL2L1—liver cancer	1.77e-05	0.000102	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ALDOB—liver cancer	1.75e-05	0.000101	CbGpPWpGaD
Trabectedin—SRC—Axon guidance—IL6—liver cancer	1.75e-05	0.000101	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.74e-05	0.0001	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ALDOB—liver cancer	1.73e-05	9.99e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—MAPK8—liver cancer	1.73e-05	9.95e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—MTHFR—liver cancer	1.71e-05	9.83e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—TERT—liver cancer	1.7e-05	9.8e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—GSTM1—liver cancer	1.7e-05	9.79e-05	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—CDKN1A—liver cancer	1.7e-05	9.79e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—MAPK14—liver cancer	1.67e-05	9.65e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CRABP1—liver cancer	1.67e-05	9.62e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—TGFB1—liver cancer	1.66e-05	9.54e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CRABP1—liver cancer	1.65e-05	9.53e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.63e-05	9.41e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TGFB1—liver cancer	1.63e-05	9.36e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—CYP1A1—liver cancer	1.61e-05	9.28e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—HPGDS—liver cancer	1.59e-05	9.14e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.58e-05	9.09e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—CYCS—liver cancer	1.57e-05	9.03e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—TNF—liver cancer	1.55e-05	8.91e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GOT1—liver cancer	1.54e-05	8.87e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GGT1—liver cancer	1.54e-05	8.87e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—KRAS—liver cancer	1.53e-05	8.84e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PRKCE—liver cancer	1.51e-05	8.7e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—KRAS—liver cancer	1.51e-05	8.67e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—MTHFR—liver cancer	1.5e-05	8.65e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.49e-05	8.58e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CPT1B—liver cancer	1.48e-05	8.53e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GLUL—liver cancer	1.48e-05	8.53e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PPARA—liver cancer	1.47e-05	8.49e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—HPGDS—liver cancer	1.46e-05	8.41e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—HPGDS—liver cancer	1.45e-05	8.33e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.44e-05	8.28e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.44e-05	8.28e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—APC—liver cancer	1.43e-05	8.26e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IGF2—liver cancer	1.43e-05	8.25e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—CDH1—liver cancer	1.43e-05	8.23e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—NR1H4—liver cancer	1.43e-05	8.22e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.42e-05	8.17e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PSMA4—liver cancer	1.41e-05	8.15e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PSMD10—liver cancer	1.41e-05	8.15e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTA3—liver cancer	1.4e-05	8.08e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—PIK3CA—liver cancer	1.38e-05	7.97e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GSTP1—liver cancer	1.38e-05	7.96e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GOT2—liver cancer	1.38e-05	7.92e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—PIK3CD—liver cancer	1.36e-05	7.86e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—HMOX1—liver cancer	1.36e-05	7.85e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—KRAS—liver cancer	1.36e-05	7.81e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—BRAF—liver cancer	1.35e-05	7.76e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—TP53—liver cancer	1.34e-05	7.71e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CSF2—liver cancer	1.34e-05	7.7e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.32e-05	7.63e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—H2AFX—liver cancer	1.32e-05	7.59e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.31e-05	7.55e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—HRAS—liver cancer	1.3e-05	7.51e-05	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—KRAS—liver cancer	1.3e-05	7.5e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PSMA4—liver cancer	1.3e-05	7.49e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PSMD10—liver cancer	1.3e-05	7.49e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CYP2E1—liver cancer	1.29e-05	7.45e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.29e-05	7.45e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PSMA4—liver cancer	1.29e-05	7.43e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PSMD10—liver cancer	1.29e-05	7.43e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTA4—liver cancer	1.28e-05	7.39e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—HRAS—liver cancer	1.28e-05	7.37e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—GSTM1—liver cancer	1.27e-05	7.32e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GOT2—liver cancer	1.26e-05	7.29e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PIK3CG—liver cancer	1.26e-05	7.27e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—PIK3CD—liver cancer	1.26e-05	7.26e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GOT2—liver cancer	1.25e-05	7.22e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.25e-05	7.21e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTA2—liver cancer	1.25e-05	7.21e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—IL6—liver cancer	1.25e-05	7.19e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—SERPINE1—liver cancer	1.25e-05	7.18e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—PIK3CA—liver cancer	1.25e-05	7.17e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—RAF1—liver cancer	1.22e-05	7.02e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PPARG—liver cancer	1.22e-05	7.02e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CYCS—liver cancer	1.21e-05	6.97e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTA1—liver cancer	1.21e-05	6.95e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—CYP1A1—liver cancer	1.2e-05	6.94e-05	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—PIK3CA—liver cancer	1.2e-05	6.89e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—NAT2—liver cancer	1.19e-05	6.87e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TERT—liver cancer	1.19e-05	6.86e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—PIK3CB—liver cancer	1.19e-05	6.85e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—MTOR—liver cancer	1.19e-05	6.85e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CYP2E1—liver cancer	1.19e-05	6.85e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GOT1—liver cancer	1.19e-05	6.84e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GGT1—liver cancer	1.19e-05	6.84e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CYP2E1—liver cancer	1.18e-05	6.79e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—HRAS—liver cancer	1.15e-05	6.64e-05	CbGpPWpGaD
Trabectedin—SRC—Developmental Biology—AKT1—liver cancer	1.15e-05	6.64e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ALDOB—liver cancer	1.14e-05	6.59e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.14e-05	6.58e-05	CbGpPWpGaD
Trabectedin—SRC—Hemostasis—AKT1—liver cancer	1.13e-05	6.51e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—RAF1—liver cancer	1.12e-05	6.48e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—MTHFR—liver cancer	1.12e-05	6.47e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—CDKN1B—liver cancer	1.12e-05	6.43e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CYCS—liver cancer	1.11e-05	6.41e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PIK3CD—liver cancer	1.11e-05	6.39e-05	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—HRAS—liver cancer	1.11e-05	6.37e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CYCS—liver cancer	1.1e-05	6.36e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—IL6—liver cancer	1.1e-05	6.35e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PPARA—liver cancer	1.1e-05	6.34e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—PIK3CB—liver cancer	1.1e-05	6.33e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—MTOR—liver cancer	1.1e-05	6.33e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—ALB—liver cancer	1.1e-05	6.31e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL2—liver cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GGT1—liver cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GOT1—liver cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CRABP1—liver cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KDR—liver cancer	1.09e-05	6.28e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GOT1—liver cancer	1.08e-05	6.24e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GGT1—liver cancer	1.08e-05	6.24e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MAPK14—liver cancer	1.08e-05	6.24e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GSTP1—liver cancer	1.07e-05	6.14e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—JUN—liver cancer	1.06e-05	6.12e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—ESR1—liver cancer	1.06e-05	6.12e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—CTNNB1—liver cancer	1.05e-05	6.08e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—HMOX1—liver cancer	1.05e-05	6.06e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—F2—liver cancer	1.05e-05	6.04e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—CDKN1B—liver cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—CDKN1A—liver cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Trabectedin—SRC—Innate Immune System—AKT1—liver cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—MAPK8—liver cancer	1.01e-05	5.79e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—APC—liver cancer	1e-05	5.78e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PIK3CG—liver cancer	1e-05	5.78e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GSTP1—liver cancer	9.81e-06	5.65e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—GSTM1—liver cancer	9.8e-06	5.65e-05	CbGpPWpGaD
Trabectedin—SRC—Adaptive Immune System—AKT1—liver cancer	9.77e-06	5.63e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—CTNNB1—liver cancer	9.74e-06	5.61e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GSTP1—liver cancer	9.72e-06	5.6e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—HMOX1—liver cancer	9.67e-06	5.57e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PIK3CB—liver cancer	9.67e-06	5.57e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—HMOX1—liver cancer	9.59e-06	5.52e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—HPGDS—liver cancer	9.54e-06	5.5e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—CDKN1A—liver cancer	9.51e-06	5.48e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—BRAF—liver cancer	9.43e-06	5.44e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PIK3CG—liver cancer	9.43e-06	5.43e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—CYP1A1—liver cancer	9.29e-06	5.35e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—STAT3—liver cancer	9.19e-06	5.3e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PPARG—liver cancer	9.1e-06	5.24e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—GSTM1—liver cancer	9.01e-06	5.19e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—GSTM1—liver cancer	8.94e-06	5.15e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PIK3CD—liver cancer	8.82e-06	5.08e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—SERPINE1—liver cancer	8.73e-06	5.03e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—MTHFR—liver cancer	8.66e-06	4.99e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—CYP1A1—liver cancer	8.54e-06	4.92e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PSMA4—liver cancer	8.5e-06	4.9e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PSMD10—liver cancer	8.5e-06	4.9e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PPARA—liver cancer	8.5e-06	4.9e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—STAT3—liver cancer	8.49e-06	4.89e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—CYP1A1—liver cancer	8.47e-06	4.88e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PIK3CD—liver cancer	8.29e-06	4.78e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GOT2—liver cancer	8.27e-06	4.76e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—ALB—liver cancer	8.18e-06	4.72e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—MTHFR—liver cancer	7.97e-06	4.59e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—MTHFR—liver cancer	7.9e-06	4.55e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—KRAS—liver cancer	7.89e-06	4.55e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—MYC—liver cancer	7.89e-06	4.54e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—RAF1—liver cancer	7.88e-06	4.54e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—TGFB1—liver cancer	7.87e-06	4.53e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PPARA—liver cancer	7.81e-06	4.5e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CYP2E1—liver cancer	7.78e-06	4.48e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PPARA—liver cancer	7.75e-06	4.46e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MTOR—liver cancer	7.69e-06	4.43e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PIK3CB—liver cancer	7.69e-06	4.43e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.63e-06	4.4e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—KRAS—liver cancer	7.29e-06	4.2e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PIK3CG—liver cancer	7.28e-06	4.19e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CYCS—liver cancer	7.28e-06	4.19e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—PIK3CA—liver cancer	7.25e-06	4.18e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PIK3CB—liver cancer	7.23e-06	4.16e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CDKN1B—liver cancer	7.22e-06	4.16e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GOT1—liver cancer	7.14e-06	4.11e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GGT1—liver cancer	7.14e-06	4.11e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CASP3—liver cancer	7.07e-06	4.08e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IL2—liver cancer	7.06e-06	4.07e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PPARG—liver cancer	7.02e-06	4.05e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.96e-06	4.01e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CCND1—liver cancer	6.89e-06	3.97e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—JUN—liver cancer	6.87e-06	3.96e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CTNNB1—liver cancer	6.82e-06	3.93e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—HRAS—liver cancer	6.71e-06	3.87e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—PIK3CA—liver cancer	6.7e-06	3.86e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PIK3CG—liver cancer	6.69e-06	3.86e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MMP9—liver cancer	6.69e-06	3.85e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—CDKN1A—liver cancer	6.66e-06	3.84e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PIK3CG—liver cancer	6.63e-06	3.82e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MAPK8—liver cancer	6.5e-06	3.75e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PPARG—liver cancer	6.46e-06	3.72e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—IL6—liver cancer	6.42e-06	3.7e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTP1—liver cancer	6.41e-06	3.69e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PPARG—liver cancer	6.4e-06	3.69e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PIK3CD—liver cancer	6.4e-06	3.69e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—HMOX1—liver cancer	6.32e-06	3.64e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—ALB—liver cancer	6.31e-06	3.64e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—HRAS—liver cancer	6.19e-06	3.57e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—VEGFA—liver cancer	6e-06	3.46e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—STAT3—liver cancer	5.94e-06	3.42e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—IL6—liver cancer	5.93e-06	3.42e-05	CbGpPWpGaD
Trabectedin—SRC—Immune System—AKT1—liver cancer	5.92e-06	3.41e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—PIK3CA—liver cancer	5.9e-06	3.4e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—GSTM1—liver cancer	5.89e-06	3.4e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PIK3CD—liver cancer	5.88e-06	3.39e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PIK3CD—liver cancer	5.83e-06	3.36e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—ALB—liver cancer	5.81e-06	3.35e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—ALB—liver cancer	5.76e-06	3.32e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—CYP1A1—liver cancer	5.59e-06	3.22e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PIK3CB—liver cancer	5.58e-06	3.21e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—MYC—liver cancer	5.52e-06	3.18e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TGFB1—liver cancer	5.51e-06	3.17e-05	CbGpPWpGaD
Trabectedin—SRC—Disease—AKT1—liver cancer	5.47e-06	3.15e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—MTHFR—liver cancer	5.21e-06	3e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PIK3CB—liver cancer	5.13e-06	2.95e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PPARA—liver cancer	5.11e-06	2.94e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—KRAS—liver cancer	5.1e-06	2.94e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PIK3CB—liver cancer	5.08e-06	2.93e-05	CbGpPWpGaD
Trabectedin—PTGS1—Metabolism—AKT1—liver cancer	4.82e-06	2.77e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—PIK3CA—liver cancer	4.69e-06	2.7e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—TP53—liver cancer	4.54e-06	2.61e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—PIK3CA—liver cancer	4.41e-06	2.54e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PIK3CG—liver cancer	4.38e-06	2.52e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—HRAS—liver cancer	4.34e-06	2.5e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PPARG—liver cancer	4.22e-06	2.43e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—IL6—liver cancer	4.15e-06	2.39e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PIK3CD—liver cancer	3.85e-06	2.22e-05	CbGpPWpGaD
Trabectedin—SRC—Signaling Pathways—AKT1—liver cancer	3.83e-06	2.21e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—ALB—liver cancer	3.8e-06	2.19e-05	CbGpPWpGaD
Trabectedin—CYP2E1—Metabolism—AKT1—liver cancer	3.6e-06	2.07e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—PIK3CA—liver cancer	3.4e-06	1.96e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PIK3CB—liver cancer	3.35e-06	1.93e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—PIK3CA—liver cancer	3.13e-06	1.8e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—PIK3CA—liver cancer	3.1e-06	1.79e-05	CbGpPWpGaD
Trabectedin—CYP2C19—Metabolism—AKT1—liver cancer	2.78e-06	1.6e-05	CbGpPWpGaD
Trabectedin—CYP2D6—Metabolism—AKT1—liver cancer	2.55e-06	1.47e-05	CbGpPWpGaD
Trabectedin—CYP2C9—Metabolism—AKT1—liver cancer	2.53e-06	1.46e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—PIK3CA—liver cancer	2.04e-06	1.18e-05	CbGpPWpGaD
Trabectedin—CYP3A4—Metabolism—AKT1—liver cancer	1.67e-06	9.62e-06	CbGpPWpGaD
